Z

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357

Watchlist Manager
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
Watchlist
Price: 21.31 CNY -0.93% Market Closed
Market Cap: 11.2B CNY
Have any thoughts about
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd?
Write Note

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
Total Receivables
ÂĄ263.5m
CAGR 3-Years
-2%
CAGR 5-Years
1%
CAGR 10-Years
10%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Receivables
ÂĄ3.3B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Receivables
ÂĄ1.1B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Receivables
ÂĄ7.5B
CAGR 3-Years
-7%
CAGR 5-Years
3%
CAGR 10-Years
10%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Receivables
ÂĄ13.2B
CAGR 3-Years
18%
CAGR 5-Years
13%
CAGR 10-Years
11%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Receivables
ÂĄ172.9m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Glance View

Market Cap
11.2B CNY
Industry
Pharmaceuticals

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. emerged on the healthcare scene in China with an unwavering focus on improving allergy treatments. Founded in 1992, the company has carved a niche in the bio-pharmaceutical industry by specializing in the research, development, and manufacturing of allergen-specific immunotherapeutic products. At its heart, Wolwo operates with a clear mission: to diminish the burden of allergic diseases. The company leverages cutting-edge bio-pharmaceutical technologies to produce allergen detection and treatment products, thereby offering innovative solutions to millions affected by allergic conditions. As allergies become more prevalent worldwide, Wolwo's focus on this segment positions it as a critical player in the healthcare market. Wolwo’s business model revolves around the development and commercialization of standardized allergen products. It generates revenue primarily from the sale of its patented therapeutic solutions targeting common allergens such as pollen, dust mites, and pet dander. This involves a deep dive into biotechnology, where their R&D teams continuously innovate to refine product offerings. The company has earned regulatory approvals across various regions, which significantly bolsters its revenue stream and expands its market footprint. Beyond just product sales, Wolwo actively engages in educational programs aimed at raising awareness about allergies, thus creating a well-rounded approach not only in tackling allergic diseases but also in ensuring long-term consumer loyalty and brand trust in a rapidly evolving market.

Intrinsic Value
22.63 CNY
Undervaluation 6%
Intrinsic Value
Price
Z

See Also

What is Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Total Receivables?
Total Receivables
263.5m CNY

Based on the financial report for Sep 30, 2024, Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Total Receivables amounts to 263.5m CNY.

What is Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 10Y
10%

Over the last year, the Total Receivables growth was -11%. The average annual Total Receivables growth rates for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd have been -2% over the past three years , 1% over the past five years , and 10% over the past ten years .

Back to Top